Back to top
more

Aerie Pharmaceuticals, Inc. (AERI)

(Delayed Data from NSDQ)

$39.78 USD

39.78
361,007

+1.23 (3.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $39.78 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?

by Zacks Equity Research

Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2017 results on May 2.

    Implied Volatility Surging for Aerie Pharmaceuticals (AERI) Stock Options

    by Zacks Equity Research

    Aerie Pharmaceuticals (AERI) warrants investors' attention based on moves in the options market lately.

      Aerie Reports Positive Data on Ophthalmic Drug Rhopressa

      by Zacks Equity Research

      Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.

        Aerie (AERI) Down 12.9% Since Earnings Report: Can It Rebound?

        by Zacks Equity Research

        Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA

          by Zacks Equity Research

          Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Bausch + Lomb announced that the FDA has set a PDUFA date on Aug 24 for its decision on the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%.

            Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction

            by Zacks Equity Research

            Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.

              Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted

              by Zacks Equity Research

              Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents

                Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?

                by Zacks Equity Research

                Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.

                  Ocular (OCUL) Reports Positive Phase III Data on Eye Drug

                  by Zacks Equity Research

                  Shares of Ocular Therapeutix, Inc. (OCUL) were up 3% following the company's announcement of positive results from its third phase III trial on lead pipeline candidate Dextenza 0.4 mg for the treatment of post-surgical ocular inflammation and pain.

                    Inotek (ITEK) Down on Poor Phase III Glaucoma Drug Data

                    by Zacks Equity Research

                    Shares of Inotek Pharmaceuticals Corporation (ITEK) plunged 71.3% after the company announced that its lead candidate trabodenoson failed to meet the primary endpoint in a phase III trial.

                      Aerie (AERI) Rhopressa Regulatory Application Delayed Again

                      by Zacks Equity Research

                      Aerie (AERI)'s NDA for lead candidate, Rhopressa, gets delayed again due to delay on the manufacturer's part.